Abstract:BACKGROUND:Human myelogenous leukemia characterized by either the non random t(8; 21)(q22; q22) or t(16; 21)(q24; q22) chromosome translocations differ for both their biological and clinical features. Some of these features could be consequent to differential epigenetic transcriptional deregulation at AML1 targets imposed by AML1-MTG8 and AML1-MTG16, the fusion proteins deriving from the two translocations. Preliminary findings showing that these fusion proteins lead to transcriptional downregulation of AML1 targets, marked by repressive chromatin changes, would support this hypothesis. Here we show that combining conventional global gene expression arrays with the power of bioinformatic genomic survey of AML1-consensus sequences is an effective strategy to identify AML1 targets whose transcription is epigenetically downregulated by the leukemia-associated AML1-MTG16 protein. RESULTS:We interrogated mouse gene expression microarrays with probes generated either from 32D cells infected with a retroviral vector carrying AML1-MTG16 and unable of granulocyte differentiation and proliferation in response to the granulocyte colony stimulating factor (G-CSF), or from 32D cells infected with the cognate empty vector. From the analysis of differential gene expression alone (using as criteria a p value < 0.01 and an absolute fold change > 3), we were unable to conclude which of the 37 genes downregulated by AML1-MTG16 were, or not, direct AML1 targets. However, when we applied a bioinformatic approach to search for AML1-consensus sequences in the 10 Kb around the gene transcription start sites, we closed on 17 potential direct AML1 targets. By focusing on the most significantly downregulated genes, we found that both the AML1-consensus and the transcription start site chromatin regions were significantly marked by aberrant repressive histone tail changes. Further, the promoter of one of these genes, containing a CpG island, was aberrantly methylated. CONCLUSION:This study shows that a leukemia-associated fusion protein can impose a distinct epigenetic repressive signature at specific sites in the genome. These findings strengthen the conclusion that leukemia-specific oncoproteins can induce non-random epigenetic changes.

AML1-ETO Promotes SIRT1 Expression to Enhance Leukemogenesis of T(8;21) Acute Myeloid Leukemia.

Identification of TET1⊣miR-22⊣CREB-MYC Signaling Reveals Potent Tumor-Suppressor Role of Mir-22 in Acute Myeloid Leukemia

High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia from Two Cohorts.

A Distinct Epigenetic Signature at Targets of a Leukemia Protein

Long Noncoding RNA SATB1-AS1 Contributes to the Chemotherapy Resistance Through the Microrna-580/ 2'-5'-oligoadenylate Synthetase 2 Axis in Acute Myeloid Leukemia.

A minicircuitry comprised of microRNA-9 and SIRT1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia.

SIRT1 Regulates the Phosphorylation and Degradation of P27 by Deacetylating CDK2 to Promote T-cell Acute Lymphoblastic Leukemia Progression.

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

A novel AML1-ETO/FTO positive feedback loop promotes leukemogenesis and Ara-C resistance via stabilizing IGFBP2 in t(8;21) acute myeloid leukemia

Epigenetic silencing of <i>miR564</i> contributes to the leukemogenesis of t(8;21) acute myeloid leukemia

Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: The role in AML1-ETO-induced growth arrest in leukemic cells

SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia

Tet2 Downregulation Promotes Aml Cell Proliferation Via Pim-1 Expression

SIRT1 Inhibition Impairs Non-Homologous End Joining DNA Damage Repair by Increasing Ku70 Acetylation in Chronic Myeloid Leukemia Cells

Inducible Expression of Aml1-Eto Fusion Protein Endows Leukemic Cells with Susceptibility to Extrinsic and Intrinsic Apoptosis

Epigenetic silencing of Bcl-2, CEBPA and p14ARF by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line

Biological function and cancerogenic mechanism of AML1-ETO fusion protein

A novel epigenetic mini-circuitry contributes to t(8;21) leukaemogenesis.

ZFP36L2, a Novel AML1 Target Gene, Induces AML Cells Apoptosis and Inhibits Cell Proliferation

Protein Lysine 43 Methylation by EZH1 Promotes AML1-ETO Transcriptional Repression in Leukemia.

Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.